Nexstim logo

Nexstim Plc’s Financial Information in 2017

08 December 2016

Nexstim Plc (NXTMH:HEX, NXTMS:STO) (“Nexstim” or the “Company”), a medical technology company with a pioneering navigated non-invasive brain stimulation system, will publish the following financial information in 2017:

- The 2016 Financial Statements Release and Half-Yearly Report July−December 2016 (H2) on Tuesday, February 28, 2017

- Half-Yearly Report January-June 2017 (H1) on Wednesday, August 16, 2017

Nexstim’s Annual Report 2016 will be published on the Company’s website on Monday, March 6, 2017.

The Annual General Meeting is tentatively scheduled to be held on Tuesday, March 28, 2017 at 10:00 am.

 

NEXSTIM PLC

Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by contacting:

Nexstim                                                                                                                          +447715163942

Martin Jamieson, Chairman and CEO                                                        martin.jamieson@nexstim.com

                                                                                                                                                                                                        

UB Securities Oy (Certified Adviser)                                                                       +358 (0)9 2538 0246

Consilium Strategic Communications                                                                     +44 (0)20 3709 5700

Mary-Jane Elliott / Ivar Milligan                                                                  nexstim@consilium-comms.com

About Nexstim Plc

Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system as the first and only FDA-cleared and CE-marked navigated Transcranial Magnetic Stimulation (nTMS) system for pre-surgical mapping of the motor and speech cortices. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE-marked for chronic neuropathic pain, major depression and stroke therapy. Nexstim's shares are listed on Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Back to Press Releases